American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Berger
    Berger
  3. Drilon
    Drilon
  4. Schram
    Schram
  5. Ladanyi
    Ladanyi
  6. Rosen
    Rosen
  7. Bandlamudi
    Bandlamudi
  8. Schultz
    Schultz
  9. Stadler
    Stadler
  10. Li
    Li

Groups

  1. Department of Medicine (66)
  2. Early Drug Development Service (66)
  3. Solid Tumor Oncology Division (66)
  4. GSK Faculty (42)
  5. Human Oncology and Pathogenesis Program (42)
  6. Genitourinary Oncology Service (26)
  7. Gynecologic Medicine Service (26)
  8. Sloan Kettering Institute Postdocs (24)
  9. Breast Medicine Service (22)
  10. Thoracic Oncology (22)
Search Within
  1. "Early Drug Development Service"
Formats
  1. Meeting Abstract (38)
  2. Journal Article (28)
Groups
  1. Department of Medicine (66)
  2. Early Drug Development Service (66)
  3. Solid Tumor Oncology Division (66)
  4. GSK Faculty (42)
  5. Human Oncology and Pathogenesis Program (42)
  6. Genitourinary Oncology Service (26)

More Groups

People
  1. David Hyman (57)
  2. David Solit (24)
  3. Michael Berger (21)
  4. Marc Ladanyi (19)
  5. Alexander Drilon (17)
  6. Alison Schram (17)

More People

Years
  1. 2024 (1)
  2. 2022 (3)
  3. 2021 (6)
  4. 2020 (11)
  5. 2019 (22)
  6. 2018 (10)

More Years

Publications
  1. Cancer Research (37)
  2. Clinical Cancer Research (29)

Results (66)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Development of a practical nomogram for personalized anemia management in patients treated with ataxia telangiectasia and Rad3-related inhibitor camonsertib
    Journal Article

    Rosen, E.; Yap, T. A.; Lee, E. K.; Højgaard, M.; Mettu, N. B.; Lheureux, S.; Carneiro, B. A.; Plummer, R.; Fretland, A. J.; Ulanet, D.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
    Meeting Abstract

    Yap, T. A.; Im, S. A.; Schram, A. M.; Sharp, A.; Balmana, J.; Baird, R. D.; Brown, J. S.; Schwaederle, M.; Pilling, E. A.; Moorthy, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • OncoKB, MSK's precision oncology knowledge base
    Meeting Abstract

    Suehnholz, S. P.; Nissan, M.; Zhang, H.; Kundra, R.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; Ladanyi, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Natural history and characteristics of ERBB2-mutated hormone receptor-positive metastatic breast cancer: A multi-institutional retrospective case-control study from AACR Project GENIE
    Journal Article

    LeNoue-Newton, M. L.; Chen, S. C.; Stricker, T.; Hyman, D. M.; Blauvelt, N.; Bedard, P. L.; Meric-Bernstam, F.; Punglia, R. S.; Schrag, D.; Lepisto, E. M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • The HER2xHER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
    Meeting Abstract

    Odintsov, I.; Khodos, I.; Espinosa-Cotton, M.; Lui, A. J.; Mattar, M.; Schram, A. M.; Schackmann, R. C.; Lammerts van Bueren, J.; Geuijen, C. A.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes
    Journal Article

    Chang, J. C.; Offin, M.; Falcon, C.; Brown, D.; Houck-Loomis, B. R.; Meng, F.; Rudneva, V. A.; Won, H. H.; Amir, S.; Montecalvo, J.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer
    Meeting Abstract

    Rosen, E. Y.; Italiano, A.; Juric, D.; Reeves, J. A.; Dima, L.; Brega, N.; Drilon, A.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A performance comparison of commonly used assays to detect RET fusions
    Journal Article

    Yang, S. R.; Aypar, U.; Rosen, E. Y.; Mata, D. A.; Benayed, R.; Mullaney, K.; Jayakumaran, G.; Zhang, Y.; Frosina, D.; Drilon, A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib
    Journal Article

    Rosen, E. Y.; Johnson, M. L.; Clifford, S. E.; Somwar, R.; Kherani, J. F.; Son, J.; Bertram, A. A.; Davare, M. A.; Gladstone, E.; Ivanova, E. V.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers
    Journal Article

    Jhaveri, K.; Chang, M. T.; Juric, D.; Saura, C.; Gambardella, V.; Melnyk, A.; Patel, M. R.; Ribrag, V.; Ma, C. X.; Aljumaily, R.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: